最高千万奖励！重庆印发创新药发展新政，创新药ETF天弘(517380)、生物医药ETF(159859)近6日连续净流入合计近3亿！

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 7.76 million yuan as of November 7, 2025, and a record high of 1.74 billion shares outstanding [2] - The biopharmaceutical ETF (159859) has also experienced strong performance, with a recent increase of 20.23% over the past six months, ranking first among comparable funds [3] Fund Performance - The innovative drug ETF Tianhong (517380) has achieved a net inflow of 78.80 million yuan over the past six days, with a peak single-day inflow of 22.82 million yuan [3] - The biopharmaceutical ETF (159859) has recorded a total net inflow of 199 million yuan in the same period, with a maximum single-day inflow of 61.78 million yuan [3] Policy Developments - Chongqing has introduced new policies to support the development of innovative drugs, offering rewards of up to 10 million yuan for the cultivation of industrial clusters [4] - The policy aims to approve 1 to 3 innovative drugs annually by 2027, with a target of reaching a total of 10 innovative drugs [4] Industry Outlook - The pharmaceutical sector showed signs of recovery in Q3 2025, with revenue and net profit growth turning positive, particularly in the medical research outsourcing sector, which saw revenue and net profit growth rates of 10.9% and 47.9%, respectively [5] - The investment sentiment in the innovation-related pharmaceutical chain, including chemical drugs and biopharmaceuticals, is expected to stabilize due to improving performance and potential policy benefits [5]